Research programme: small molecule therapeutics - e-Therapeutics

Drug Profile

Research programme: small molecule therapeutics - e-Therapeutics

Alternative Names: ETS 2123; ETS 5200; ETS 6114; ETS 7211; ETS2300; ETS2400; ETS6200; ETX 6201; ETX 6765

Latest Information Update: 04 Apr 2016

Price : $50

At a glance

  • Originator e-Therapeutics
  • Class Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Neurodegenerative disorders; Viral infections
  • Discontinued Age-related macular degeneration; Pain

Most Recent Events

  • 22 Mar 2016 Preclinical trials in Viral infections in United Kingdom (unspecified route)
  • 10 Jul 2015 Preclinical development is ongoing in United Kingdom
  • 07 Oct 2014 Preclinical development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top